Purple toes syndrome following stroke thrombolysis and warfarin therapy.
Nambour General Hospital, Nambour, Queensland, Australia.
T
T
Mooney
P
P
Joseph
D058186:Acute Kidney Injury / Q000209:etiology; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications; D017700:Embolism, Cholesterol / Q000139:chemically induced* / Q000150:complications; D017984:Enoxaparin / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000188:drug therapy* / Q000209:etiology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013577:Syndrome; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use; D014034:Toes / Q000098:blood supply*; D014859:Warfarin / Q000009:adverse effects* / Q000627:therapeutic use
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D014859:Warfarin; D010959:Tissue Plasminogen Activator